Cipla is realigning its “capital allocation choices” in key business areas, adopting a seemingly more measured approach across its US generic R&D and specialty segments. It is also consolidating various components of its India business – prescription, trade generics (unbranded generics) and wellness – to drive synergies across operations.
Cipla’s global CEO and managing director, Umang Vohra, said that for the US generics business the company plans to recalibrate its investments in R&D
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?